Navigation Links
FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S.
Date:4/17/2008

Agency Approves Expansion of Company's Phase 3 Study for Wet AMD after

90-day Review of Safety Data

FREMONT, Calif., April 17 /PRNewswire/ -- NeoVista, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company's request to expand the number of sites participating in its pivotal Phase 3 trial from 10 to 30 in the United States. The approved expansion of CABERNET (CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy) trial, which seeks to evaluate the safety and efficacy of the company's novel epiretinal brachytherapy for the wet form of age-related macular degeneration (AMD), was dependent on the FDA's review of 90-day safety data, typical of new-to-market medical devices.

"With this expansion to 30 sites, we will not only be able to recruit more patients at a higher rate, taking us one step closer to commercialization in the United States, but it will also allow additional retina specialists to see the benefits of our novel therapy first-hand while treating their patients," said John N. Hendrick, President and CEO of NeoVista. "It's an exciting time at NeoVista with our recent CE Mark approval in the EU and the FDA approval of our trial expansion. We are getting closer and closer to seeing our investigational therapy become an approved treatment option for millions of patients worldwide afflicted with wet AMD."

CABERNET is a multicenter, randomized, controlled study that will enroll 450 subjects at clinical centers worldwide. The study will evaluate the safety and efficacy of NeoVista's epiretinal brachytherapy, delivered utilizing a limited vitrectomy, concomitant with two intravitreal injections of the FDA-approved antiangiogenic therapy Lucentis(R) (ranibizumab) versus Lucentis alone. For those enrolled in the trial arm utilizing brachytherapy, Lucentis is injected once at the time of the surgery and once again 30 days later. The co-primary endpoints in the CAB
'/>"/>

SOURCE NeoVista, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
2. Chinese SFDA Grants Immtech Fast Track Status
3. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
4. NTMir Announces Research Grants for Epidemiology and Household Water as Source of Infection
5. FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents
8. FDA Grants Priority Review for PROMACTA(R) (eltrombopag)
9. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
10. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
11. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)BETHESDA, Md., Dec. 4 Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurr
(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab
(Date:12/3/2009)NEW YORK, Dec. 3 Guidepoint Global, LLC , a leading primary research firm, today announced the launch of their Sleep Apnea Tracker, a monthly longitudinal data release that monitors and projects tre
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Cepheid Receives Grant to Develop Ten Color Real Time PCR Detection Technology for Use in the GeneXpert 28R 29 System 4584 1Cepheid Receives Grant to Develop Ten Color Real Time PCR Detection Technology for Use in the GeneXpert 28R 29 System 4584 2Cepheid Receives Grant to Develop Ten Color Real Time PCR Detection Technology for Use in the GeneXpert 28R 29 System 4584 3Cepheid Receives Grant to Develop Ten Color Real Time PCR Detection Technology for Use in the GeneXpert 28R 29 System 4584 4Brain computer interface developed at Brown begins new clinical trial 8783 1Brain computer interface developed at Brown begins new clinical trial 8783 2Brain computer interface developed at Brown begins new clinical trial 8783 3Brain computer interface developed at Brown begins new clinical trial 8783 4Watson Files FDA Application for Generic Mucinex 28R 29 D 48412 1Watson Files FDA Application for Generic Mucinex 28R 29 D 48412 2Watson Files FDA Application for Generic Mucinex 28R 29 D 48412 3
...LANTA, July 7 GeoVax Labs, Inc. (OTC,Bulletin Boa...armaceutical,company specializing in the preventio...ided an operational update on the company,s progre...nical trial testing and,plans to proceed into ther...uccessful human trials evaluating GeoVax AIDS vacc...
... GeneOhm(TM) Cdiff Assay Submitted for FDA Clearan...of BD (Becton, Dickinson and Company) (NYSE: BDX ...m(TM) Cdiff molecular assay for the rapid diagnosi... (CDI). It is the first CDI,diagnostic test that o...t,procedure. BD has also submitted this assay to t...
Other Medicine Technology:GeoVax Reports Progress on Its AIDS Vaccine Technology 2GeoVax Reports Progress on Its AIDS Vaccine Technology 3GeoVax Reports Progress on Its AIDS Vaccine Technology 4GeoVax Reports Progress on Its AIDS Vaccine Technology 5BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections 2BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections 3
(Date:12/4/2009)NEW YORK, Dec. 4 Care Investment Trust Inc. (NYSE: CRE ) ("Care" or the "Company") today announced that its Board of Directors has declared a dividend of $0.17 per share of common stock. The div
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)KANSAS CITY, Mo., Dec. 4 The large, two-day free health clinic sponsored by the National Association of Free Clinics (NAFC) in Kansas City on Wednesday and Thursday is not just for the sick but also
(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
Breaking Medicine News(10 mins):Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Free Health Clinic Event Is Not Just for the Sick 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4
...s today filed an appeal in their challenge of a co...eld by the Wisconsin Alumni Research,Foundation (W... for Taxpayer and Consumer,Rights, and the Public ...s requested a re-examination of the patent,in July...
...nnipeg (July 18, 2008) Funding of $4.4 million fr...R) was announced today by Steven Fletcher, MP for ... Secretary for Health, on behalf of Tony Clement, ...Health Commission of Canada is contributing $250,0...
...chigan State University scholar refutes commonly h..., more emotionally unstable and harder to get alon...ith the findings, employers are urged to guard aga...ent, and two colleagues studied the relationship b...
...paign to raise awareness, of the importance of t... compliance rates across the United St...ation, a,nonprofit organization dedicated to healt...ay, July 19 in conjunction,with the Ebenezer Afric...
...eld,United Concordia Companies, Inc. and Catholic ...es and lifestyles for Pittsburghers. Beginning at ...y 19, a free clinic will,offer health information ...re than other aspects of health care. The percepti...
...t old drug offers new hope , , FRIDAY, Jul...ne step back in the search for treatments against ...e July 19 issue of The Lancet , an older drug cal...er,s -- even though it cleared dementia-linked amy...
Other Medicine News:Health News:Consumer Groups File Appeal on Challenge of Human Stem Cell Patent Held By WARF 2Health News:CIHR announces $4.4 million to improve mental health of Canadians 2Health News:Studies refute common stereotypes about obese workers 2Health News:The COSHAR Foundation Participates in Annual Women's Health Awareness Day 2Health News:The COSHAR Foundation Participates in Annual Women's Health Awareness Day 3Health News:Highmark Blue Cross Blue Shield, United Concordia and Catholic Charities Join Forces to Offer Free Health, Dental Services This Saturday 2Health News:Alzheimer's Research Brings Progress, Setbacks 2Health News:Alzheimer's Research Brings Progress, Setbacks 3Health News:Alzheimer's Research Brings Progress, Setbacks 4
Creatine Kinase (CK-NAC)
Alanine Aminotransferase (ALT) GPT
Alkaline Phosphatase (ALP) (DIMENSION)
...ost other EMR,systems require you to,change th...c patient charting,solution designed to fit into...round,five specific criteria to,enhance overal...oPad allows you to see,more patients in the same...
Medicine Products: